Improving the Lives of Patients, Bioness’ StimRouter™ Neuromodulation System Currently Being Implanted to Manage Chronic Pain

VALENCIA, Calif., Sept. 7, 2016 /PRNewswire/ — Bioness, Inc., the leading provider of cutting edge, clinically supported rehabilitation therapies, today announced a series of successful StimRouter Neuromodulation System implantations to manage chronic pain conditions originating from varied peripheral neuralgias. As a minimally invasive device designed to reduce pain by specifically targeting the affected peripheral nerve, StimRouter is designed to be a cost-effective alternative to injections, ongoing medication regiments, and complex surgeries.

Nearly 100 million Americans suffer from debilitating chronic pain, which may be experienced across all areas of the body including the arm, torso and leg. Chronic pain is often secondary to a primary condition (e.g. stroke) and can also result from entrapment or compression syndromes, post-surgical complications or failed surgeries.

“For many years we have had limited solutions to help our patients manage their debilitating pain,” shared William Porter McRoberts, MD, a trained Physiatrist and Interventional Spine and Pain Management Specialist based in Fort Lauderdale, Florida. “As hard as it is to understand the impact of one’s pain, it is easy to see when relief is delivered. I’m very pleased with how well my patients are responding to the StimRouter and believe that the technology will be suitable for a greater range of patients in the future.”

StimRouter was the first FDA cleared non-drug, long-term, minimally invasive neuromodulation medical device indicated to treat chronic pain of a peripheral nerve origin. The patient controlled device is an adjunct to other modes of therapy (e.g., medications) and is being well received by patients and clinicians alike.

The StimRouter is currently being implanted at prestigious clinical institutions across the country to treat chronic peripheral nerve pain, with specific focus on the following conditions or areas:

  • Axillary nerve (e.g. post-stroke shoulder pain)
  • Ulnar nerve (e.g. cubital tunnel syndrome)
  • Ilioinguinal (e.g. post-surgical hernia complication)
  • Superior Cluneal nerve (e.g. lower back neuralgia)

“As clinicians and patients continue to look for effective and sustainable ways to treat and manage pain, it is rewarding to see patients thrive with our StimRouter technology,” shared Todd Cushman, President and CEO of Bioness. “Pain is more than just a barrier to a comfortable life and pursing employment, it can be what prevents patients from being able to seek therapy to rehabilitate an injury or illness.”

For more information on the StimRouter as well as videos of real patients sharing their StimRouter experience, please visit www.stimrouter.com.

About StimRouter Neuromodulation System
StimRouter is cleared by the FDA to treat chronic pain of peripheral nerve origin. StimRouter is a minimally invasive neuromodulation medical device consisting of a thin, implanted lead with conductive electrode, external pulse transmitter (EPT), and hand-held wireless patient programmer. Electrical signals are transmitted transdermally from the EPT through the electrode, down the lead to the target nerve. StimRouter is programmed at the direction of the physician to meet patient requirements but is controlled by the patient to address the patients specific, changing pain management needs.

About Bioness Inc.
Bioness is the leading provider of innovative technologies helping people regain mobility and independence. Bioness solutions include external and implantable functional electrical stimulation (FES) systems, robotic systems and software-based therapy programs providing functional and therapeutic benefits for individuals affected by pain, central nervous system disorders and orthopedic injuries. Individual results vary. Consult with a qualified physician to determine if this product is right for you. Contraindications, adverse reactions and precautions are available online at www.bioness.com

Media Relations Contact Information
Next Step Communications

StimRouter™ and Bioness® are trademarks of Bioness, Inc. | www.bioness.com | Rx Only | Additional information about StimRouter can be found at www.stimrouter.com.


To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/improving-the-lives-of-patients-bioness-stimrouter-neuromodulation-system-currently-being-implanted-to-manage-chronic-pain-300323378.html

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button